Medistem Announces Discovery: Menstrual Blood Yields Novel Stem Cell Population
Market Wire, November 15, 2007
A paper describing a novel stem cell population derived from menstrual blood has been published by Medistem Laboratories, Inc. (OTC BB:MDSM.OB - News) (Frankfurt:S2U.F - News) in collaboration with the Bio-Communications Research Institute in Wichita, Kansas, the University of Alberta, and the University of Western Ontario. The Journal of Translational Medicine has published the paper which is titled, "Endometrial Regenerative Cells: A Novel Stem Cell Population". The publication is free to read at www.translational-medicine.com/content/5/1/57
"I view the discovery of the Endometrial Regenerative Cell (ERC) as a great step forward in providing an ethical, easily accessible, and potentially highly useful adult stem cell for treatment of numerous degenerative conditions," said Dr. Xiaolong Meng, head of the research team. He continued, "ERC cells can be converted into basically all the major tissues of the body, including the liver, lung, pancreas, brain, heart, blood vessel, and muscle. Additionally, these cells produce 100,000 times the number of growth factors found in cord blood, opening the door to numerous regenerative applications."
The study has exhibited that menstrual blood stem cells possess special cellular and molecular characteristics. This is the first publication in a peer-reviewed medical journal demonstrating these facts.
"The ability to take a cell and differentiate it into the tissue type needed by the body creates a world of opportunity in the world of organ and tissue regeneration," said Neil Riordan, PhD, President and CEO of Medistem. He added, "With IP filed around the cell line, we have begun taking the next steps in the commercialization process. Currently, our collaborators at Western Ontario, Alberta, and the Bio-Communications Research Institute are doing a series of pre-clinical studies to establish efficacy data in a variety of indications. The indications currently being assessed include diabetes, liver cirrhosis, lung fibrosis, organ rejection, and multiple sclerosis. Should the data gathered prove strong in one or all the indications the next step will be to file INDs with the FDA and move into clinical trials," said Riordan.
About Medistem Laboratories, Inc.
Medistem Laboratories is a biotechnology company that discovers, develops, and commercializes adult stem cell products that address serious medical conditions. Medistem's primary focus is drug discovery and development, however, Medistem also outlicenses proprietary technology from their growing intellectual property portfolio to commercial entities in markets where stem cell administration is permissible. Medistem believes it is well positioned to be a leading developer of adult stem cell products given its licensee relationships and collaborative efforts with respected institutions.
Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking information.
This document does not constitute an offer to sell or a solicitation of an offer to buy any of our securities. This document contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements may include projections of matters that affect revenue, the ability to develop or license certain technologies; operating expenses or net earnings; projections of capital expenditures; projections of growth; hiring plans; plans for future operations; financing needs or plans; plans relating to the company's products and services; and assumptions relating to the foregoing.
Some of the important factors that could cause the company's actual results to differ materially from those projected in forward-looking statements made by the company include, but are not limited to, the following: technology development limitations, intense competition, risk of business interruption, management of rapid growth, need for additional financing, regulatory approvals and requirements, dependence on key personnel and research, management and other administrative costs.
These factors are discussed in greater detail in the company's quarterly and annual periodic reports, all as filed with the Securities and Exchange Commission.